We have previously written about the benefits of Azithromax (Z-pack) in a variety of chronic diseases—and about early treatment of intracellular infections to limit the risk of developing a chronic infection. Azithromax is safe and available, and has been shown to be effective at stopping inflammation and blood clots, after influenza and other viral illnesses. Azithromax has been shown to reduce the risk of future cardiovascular events in patients with cardiac disease.

Azithromax and is now being considered as a potential early treatment for newly diagnosed covid-19 patients, to reduce inflammation and reduce the risk of life-threatening blood clots. Azithromax may also benefit covid-19 patients by treating underling chronic infections, which compound the adverse effects of covid-19. Early treatment of covid-19 with Azithromax could potentially prevent severe disease, reduce the risk of death, and reduce the risk of long-term complications.

https://onlinelibrary.wiley.com/doi/epdf/10.1002/rmv.2163